Jannot Anne-Sophie, Usel Massimo, Bouchardy Christine, Schubert Hyma, Rapiti Elisabetta
Geneva Cancer Registry, University of Geneva, CMU, 1211, Geneva 4, Switzerland.
Division of Clinical Epidemiology, Geneva University Hospital, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland.
Cancer Causes Control. 2017 Sep;28(9):921-928. doi: 10.1007/s10552-017-0928-5. Epub 2017 Jul 27.
We investigated whether the relationship between family history (FH) of breast cancer and survival of women with breast cancer is related to the quality of care received, once adjusted for other prognostic variables using data from the Geneva population-based cancer registry and quality of care indicators defined by the European Society of breast cancer specialists (EUSOMA).
We included non-metastatic malignant breast tumor patients who had their surgery between 2001 and 2010. We assessed the association between FH and patient and tumor characteristics on one hand, and each quality of care indicator and an overall score of quality of care, on the other hand, through logistic regression. We assessed the impact of FH and the quality of care-score on 5-year survival with Cox regression adjusting for patient and tumor characteristics.
2,672 patients were included in the study. Women with a positive FH were younger, more likely from Switzerland, screen detected, had positive estrogen and progesterone receptor status, and had smaller and ductal tumors. A positive FH was also associated with better management for several quality indicators. Women with a positive FH had a better crude survival (Hazard Ratio 0.61, p = 0.006). This association was not substantially affected when adjusting for quality of care. However, the effect of FH did not persist when also adjusting for patient and tumor characteristics.
A positive FH of breast cancer is associated with earlier breast cancer diagnosis, better tumor features, and higher quality of care. These factors explain the better survival observed among breast cancer women with a positive FH as compared to women without positive FH.
我们利用来自日内瓦基于人群的癌症登记处的数据以及欧洲乳腺癌专家协会(EUSOMA)定义的医疗质量指标,在对其他预后变量进行调整后,研究乳腺癌家族史(FH)与乳腺癌女性生存率之间的关系是否与所接受的医疗质量相关。
我们纳入了2001年至2010年间接受手术的非转移性恶性乳腺肿瘤患者。一方面,我们通过逻辑回归评估FH与患者及肿瘤特征之间的关联,另一方面,评估每个医疗质量指标与医疗质量总体评分之间的关联。我们使用Cox回归在对患者和肿瘤特征进行调整后,评估FH和医疗质量评分对5年生存率的影响。
2672名患者纳入研究。FH呈阳性的女性更年轻,更有可能来自瑞士,通过筛查发现,雌激素和孕激素受体状态为阳性,肿瘤较小且为导管癌。FH呈阳性还与多个质量指标的更好管理相关。FH呈阳性的女性粗生存率更高(风险比0.61,p = 0.006)。在对医疗质量进行调整后,这种关联没有受到实质性影响。然而,在对患者和肿瘤特征进行调整后,FH的影响不再持续。
乳腺癌FH呈阳性与乳腺癌的早期诊断、更好的肿瘤特征以及更高的医疗质量相关。这些因素解释了与FH呈阴性的女性相比,FH呈阳性的乳腺癌女性生存率更高的原因。